Clinical trial · Interventional
A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.
Effectiveness of RaproCell in Alleviating the Side Effects of Chemotherapeutic Agents, Without Adversely Impacting the Overall Success of the Agents on Cancer Cells.
NCT05137067CI-TRIAL-00087510completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will assess the effectiveness of a natural nutraceutical in treating the known side effects of chemotherapeutic agents in cancer patients.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel). | Drug | — | UNRESOLVED |
| Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell) | Dietary Supplement | — | UNRESOLVED |
| Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (9)
- type
- OTHER
- label
- Chemotherapeutic agent A (Docetaxel)
- description
- The patients with breast cancer will receive chemotherapeutic agent A
- interventionNames
- Drug: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).
- type
- PLACEBO_COMPARATOR
- label
- Chemotherapeutic agent A (Docetaxel) plus placebo
- description
- The patients with breast cancer will receive chemotherapeutic agent A plus a placebo.
- interventionNames
- Drug: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo
- type
- ACTIVE_COMPARATOR
- label
- Chemotherapeutic agent A (Docetaxel) plus RaproCell
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 25 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: Active breast cancer patients taking one of the studies listed drugs within the age range. Active lung cancer patients taking one of the studies listed drugs within the age range. Active prostate cancer patients taking one of the studies listed drugs within the age range. \- Exclusion Criteria: Anyone without the three types of cancer (breast cancer, lung cancer, prostate cancer) listed in inclusion criteria. \-
References
Publications (0)
Data not yet available
No reference posted for this study.